We evaluated the efficacy of CHK1 and BRD4 small‐molecule inhibitors, AZD7762 and OTX‐015, respectively, in HCC patient‐derived xenograft organoid (HCC‐PDXO) models. This evidence concerns the gene BRD4 and hepatocellular carcinoma.